CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2013 ASH Annual Meeting and Exposition
Oncology Conference Multimedia
View more videos >>
Dr. Amengual on Novel Therapeutics in Lymphoma
Dr. Byrd Provides an Update on Ibrutinib in CLL
Dr. Pierluigi Porcu Discusses CTCL Research
Oncology Conference Articles
Idelalisib Improves Survival in High-Risk CLL
Combination treatment with idelalisib plus rituximab was associated with a >70% improvement in OS in patients with high-risk relapsed/refractory CLL.
Quizartinib Active in AML at Lower Doses
Almost half of patients with relapsed/refractory AML had complete remissions when treated with quizartinib, which also had a more favorable safety profile as compared with higher doses.
Brentuximab Vedotin Shows Activity in B-Cell Lymphomas
Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.
Latest Data Further Support Ibrutinib's Efficacy in CLL
Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.
Telomerase Inhibitor Imetelstat Shows Promise in Myelofibrosis
Imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.
New Drug Class Shows Activity in Refractory Multiple Myeloma
The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.
Ofatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLL
Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.
Ibrutinib Induces Rapid, Durable Responses in WaldenstrÃ¶m's Macroglobulinemia
The BTK inhibitor ibrutinib rapidly reduced serum immunoglobulin M levels and improved hematocrit levels in patients with relapsed or refractory WaldenstrÃ¶m's macroglobulinemia, and the responses to ibrutinib were durable.
IPI-145 Has Activity in Relapsed/Refractory CLL
Almost half of patients with relapsed or refractory chronic lymphocytic leukemia attained objective responses when treated with an oral inhibitor of phosphoinositide-3-kinase-delta and -gamma.
Bcl-2 Inhibitor ABT-199 Shows Promise in CLL and SLL
ABT-199, an orally bioavailable selective inhibitor of the Bcl-2 protein as monotherapy, induced remissions in patients with relapsed/refractory CLL and SLL, including adverse-risk subsets of patients.
Continuous Lenalidomide Deemed a Standard of Care For Newly Diagnosed Multiple Myeloma
The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.
Obinutuzumab Regimen Slows CLL Compared With Rituximab
Patients with chronic lymphocytic leukemia and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab instead of rituximab.
Engineered T-Cells Achieve Dramatic Results in Resistant CLL
Treatment with engineered donor T cells led to substantial tumor regression in patients with posttransplant relapsed B-cell malignancies, results of a small clinical study showed.
Treating Precursor Disease May Stall Multiple Myeloma Progression
Intervention in early or "smoldering" myeloma with a three-drug regimen led to complete responses in a group of high-risk patients, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.
Longer Bortezomib Duration Linked to Improved Survival in Multiple Myeloma
A higher cumulative dose of bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve OS in patients with previously untreated multiple myeloma.
ASH 2013 Preview: CAR Modified T Cells, Novel Assays, and Ibrutinib
To gain insight into the studies being presented at the ASH Annual Meeting, we interviewed Marcel R.M. van den Brink, MD, PhD, on abstracts being presented by faculty at Memorial Sloan-Kettering Cancer Center.
Burden of Cardiovascular Disease in Prostate Cancer
The Role of Patient Education in Side Effect Management
Sorting Through the Alphabet Soup of Evolving Treatments in CLL
FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma
Will Precision Medicine Displace the Randomized Trial?
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.